Welcome to the e-CCO Library Archive!

Filter:

P387. Reduced length of hospitalisation and treatment costs with infliximab versus ciclosporin in patients with severe ulcerative colitis

Authors:

M. Lowenberg¹, N. Duijvis¹, C. Ponsioen¹, W. Bemelman², G. van den Brink¹, P. Fockens¹, G. D'Haens¹, ¹AMC, Gastroenterology, Amsterdam, Netherlands, ²AMC, Surgery, Amsterdam, Netherlands

P387

Disease course and colectomy rate in ulcerative colitis: a follow-up cohort study of a tertiary referral center in Tuscany

Authors:

N. Manetti*, S. Bagnoli, F. Rogai, M. Coppola, G. Vannozzi, M. Milla, V. Annese

AOU Careggi University Hospital, Division of Gastroenterology, Florence, Italy

P388.

Perifistular application of adipose-derived mesenchymal stem cells – experimental study

Authors:

O. Ryska¹, Z. Serclova¹, O. Mestak², E. Matouskova³, P. Vesely², I. Mrazova⁴, O. Luksan⁴, ¹Central Military Hospital, Department of Surgery, Prague, Czech Republic, ²Hospital Bulovka, Department of Plastic Surgery, Prague, Czech Republic, ³3rd Medical Faculty Charles University, Department of Burns Medicine, Prague, Czech Republic, ⁴Institute for Clinical and Experimental Medicine, Centrum of Experimental Medicine, Prague, Czech Republic

P388. Immunological changes in IBD patients responding to low-dose naltrexone treatment

P388. Recurrence and long term results of laparoscopic versus open ileo-colonic resection in Crohn's disease. A prospective longitudinal study

Authors:

E. Iaculli¹, C. Fiorani², O. Sara², L. Biancone³, T. Giorgia², R. Pezzuto³, R. Scaramuzzo³, A.L. Gaspari², G. Sica², ¹Guy's and St Thomas' Hospital, Surgery, London, United Kingdom, ²Tor Vergata Roma, Italy, ³Tor Vergata, Italy

P388

Fistula Healing in Perianal Crohn's Disease - With or Without Anti-TNF Therapy?

Authors:

N.A. Yassin*¹, A. Askari², L. Ferrari², O. Faiz², J. Warusavitarne², R. Phillips², A. Hart³

¹St Mark's Hospital, Colorectal Surgery & IBD Unit, London, United Kingdom, ²St Mark's Hospital, Colorectal Surgery, London, United Kingdom, ³St Mark's Hospital, IBD Unit, London, United Kingdom

P389.

Patients' self-assessment of their knowledge about ulcerative colitis indicates level of adherence

Authors:

W. Kruis¹, H. Grümmer², B. Gerhard³, S. Blau⁴, M. Düffelmeyer⁵, S. Ceplis-Kastner⁶, B. Reimers⁷, ¹Evangelisches Krankenhaus Kalk, University of Cologne, Köln, Germany, ²Praxis für Innere Medizin, Facharzt für Innere Medizin, Potsdam, Germany, ³Praxis für Innere Medizin, Fachärztin für Innere Medizin, Berlin-Hellersdorf, Germany, ⁴Praxis für Innere Medizin, Fachärztin für Innere Medizin, Frakfurt am Main, Germany, ⁵IOMTech GmbH, Statistics, Berlin, Germany, ⁶Ferring Arzneimittel GmbH, Pharmaceutical Department, Kiel, Germany, ⁷Ferring Arzneimittel GmbH, Specialty Care, Kiel, Germany

P389. Mucosal healing in patients with ulcerative colitis on maintenance infliximab treatment

P389. Reactive oxygen metabolites and antioxidants as biomarkers of disease severity in ulcerative colitis

Authors:

B. Canbakan¹, M. Tuncer¹, E. Koroglu¹, A. Sonsuz¹, H. Senturk², ¹Istanbul University Cerrahpasa Medical Faculty, Gastroenterology, Istanbul, Turkey, ²Bezmi Alem University, Gastroenterology, Turkey

P389

A double-blind clinical trial on Trichuris suis

Authors:

ova (TSO) in active Crohn's disease resulted in a significant placebo effect both in patients and investigators without objective evidence of reduced inflammation

J. Schölmerich*¹, K. Fellermann², F.W. Seibold³, G. Rogler⁴, J. Langhorst⁵, S. Howaldt⁶, G. Novacek⁷, A.M. Petersen⁸, O. Bachmann⁹, H. Matthes¹⁰, N. Hesselbarth¹¹, T. Klugmann¹², J. Wehkamp¹³, J. Klaus¹⁴, C. Ott¹⁵, R. Greinwald¹⁶, R. Mueller¹⁶

¹Klinikum der Johann Wolfgang Goethe-Universität Frankfurt a.M. , Ärztliche Direktion, Frankfurt a.M., Germany, ²UK-SH Campus Lübeck, Abt. Gastroenterologie, Lübeck, Germany, ³Spital Netz Bern Tiefenau, Abt. Gastroenterologie, Bern, Switzerland, ⁴University of Zurich, Division of Gastroenterology and Hepatology, Zurich, Switzerland, ⁵Kliniken Essen-Mitte, Integrative Gastroenterologie, Internal and Integrative Medicine, Essen, Germany, ⁶Hamburgisches Forschungsinstitut für CED, HaFCED GmbH&Co.KG, Hamburg, Germany, ⁷Medizinische Universität Wien, Universitätsklinik für Innere Medizin III, Vienna, Austria, ⁸Hvidovre University Hospital, Department of Gastroenterology, Hvidovre, Denmark, ⁹Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Hannover, Germany, ¹⁰Gemeinschaftskrankenhaus Havelhöhe, Abt. Gastroenterologie, Berlin, Germany, ¹¹Ärztehaus am Klinikum, Private Practice, Schwalmstadt, Germany, ¹²Gastroenterologische Gemeinschaftspraxis, Private practice, Leipzig, Germany, ¹³Robert-Bosch-Krankenhaus, Abt. Innere Medizin I, Stuttgart, Germany, ¹⁴Universitätsklinikum Ulm, Klinik für Innere Medizin I, Ulm, Germany, ¹⁵University Hospital of Regensburg, Dept. of Internal Medicine I, Regensburg, Germany, ¹⁶Dr Falk Pharma GmbH, Dept of Clinical Research & Development, Freiburg, Germany

P390.

Patient perceptions on the impact of coffee consumption in inflammatory bowel disease: friend or foe?

Authors:

C. Barthel^1,2, S. Wiegand^1,3, S. Scharl¹, M. Scharl¹, P. Frei^1,4, M. Fried¹, S.R. Vavricka^1,5, N. Wiegand^1,3, G. Rogler¹, L. Biedermann¹, ¹University Hospital Zurich, Gastroenterology & Hepatology, Zurich, Switzerland, ²Robert-Bosch-Hospital Stuttgart, Division of Gastroenterology and Hepatology, Stuttgart, Germany, ³Klinik St. Anna, Luzern, Division of Gastroenterology and Hepatology, Luzern, Switzerland, ⁴Seespital Horgen, Gastroenterology & Hepatology, Horgen, Switzerland, ⁵Hospital Triemli, Gastroenterology & Hepatology, Zurich, Switzerland

P390. Medical and surgical treatment of haemorrhoids and anal fissure in Crohn's disease

P390. Re-introduction of infliximab after consecutive failure of infliximab and adalimumab is beneficial in refractory Crohn's disease

Authors:

J.F. Brandse¹, C.P. Peters¹, E.J. Eshuis¹, M. Lowenberg¹, C.Y. Ponsioen¹, G.R. van den Brink¹, G.R.A.M. D'Haens¹, ¹Academic Medical Center, Gastroenterology and Hepatology, Amsterdam, Netherlands

P390

Thiopurines are more effective in Crohn's Disease than in Ulcerative Colitis, despite a global high rate of treatment failure: A single centre experience in the use of thiopurines in the era of biologics

Authors:

C. Suarez Ferrer*, Y. Gonzalez Lama, G.P. Irene, V. Matallana Royo, M. Calvo Moya, M.I. Vera Mendoza, A.S.R. Leticia, L. Abreu Garcia

Hospital Puerta De Hierro, Gastroenterology, Madrid, Spain

P391.

Patient co-payments in Latvia and Estonia and the use of azathioprine

Authors:

V. Mokricka, E. Krustins, A. Pukitis, J. Pokrotnieks, Pauls Stradins Clinical University Hospital, Centre of Gastroenterology, Hepatology and Nutrition, Riga, Latvia

P391. Rates of “patient-defined” remission with adalimumab in patients with ulcerative colitis: subanalysis of ULTRA 1 and ULTRA 2

Authors:

J. Lewis¹, S. Ghosh², W. Sandborn³, G. Van Assche⁴, G. D'Haens⁵, A. Lazar⁶, S. Eichner⁷, B. Huang⁷, A. Robinson⁷, R. Thakkar⁷, ¹University of Pennsylvania Perelman School of Medicine, Philadelphia, United States, ²University of Calgary, Calgary, Canada, ³University of California San Diego, La Jolla, United States, ⁴University of Toronto, Toronto, Canada, ⁵Academic Medical Center, Amsterdam, Netherlands, ⁶AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁷Abbott Laboratories, Abbott Park, United States

P391. Risk of short-term postoperative complications in patients treated with azathioprine for Crohn's disease. A single center experience

P391

Effect of Adalimumab on Clinical Laboratory Parameters in Paediatric Crohn's Disease Patients from IMAgINE 1

Authors:

J. Hyams*¹, J. Rosh², J. Markowitz³, J. Kierkus⁴, M. Dubinsky⁵, D. Turner⁶, W. Faubion⁷, S. Eichner⁸, A. Lazar⁹, Y. Li⁸, R.B. Thakkar⁸

¹Connecticut Children’s Medical Centre, Gastroenterology, Hartford, United States, ²Goryeb Children’s Hospital/Atlantic Health, Gastroenterology, Morristown, United States, ³Cohen’s Children’s Medical Centre of NY, Gastroenterology, New Hyde Park, United States, ⁴Children’s Memorial Health Institute, Gastroenterology, Warsaw, Poland, ⁵Mount Sinai Hospital, Gastroenterology, New-York, United States, ⁶Shaare Zedek Medical Centre, Gastroenterology, Jerusalem, Israel, ⁷Mayo Clinic, Gastroenterology, Rochester, United States, ⁸AbbVie Inc., Global Pharmaceutical Research & Development, North Chicago, United States, ⁹AbbVie Deutschland GmbH & Co, KG, GPRD, Ludwigshafen, Germany

P392.

Patient knowledge of reproductive issues in inflammatory bowel disease is only one of many factors that affect decisions regarding family planning

Authors:

V.W. Huang, K.I. Kroeker, K.J. Goodman, K.M. Hegadoren, R.N. Fedorak, University of Alberta, Medicine, Edmonton, Canada

P392. Determinants of length of hospital stay in patients undergoing index operations for ulcerative colitis


All Abstracts Documents Images Podcasts Webcasts
search by: